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Abstract
Background: Stroke has a considerable socio-economic impact worldwide and is the leading cause of disabilities
in the Western world. Economic studies of stroke focus merely on physical aspects and clinical interventions. To
our current knowledge there is no comprehensive economic study investigating the economic impact of stroke
including psychological and social aspects. The €-Restore4Stroke project, part of a large comprehensive research
programme Restore4Stroke, aims to investigate the total economic impact of stroke in the Netherlands.
Methods: Two trial-based economic evaluation studies will be conducted within the €-Restore4Stroke project: one
focussing on a self-management intervention and one on an augmented cognitive behavioural therapy
intervention. Both include cost-effectiveness analyses and cost-utility analyses as primary research methods.
Furthermore, a cost-of-illness study investigating costs after stroke attached to a cohort study and a record linkage
study in which four databases are linked to investigate patterns of health care consumption before and after
stroke, are embedded in €-Restore4Stroke. All studies will be performed from a societal perspective. The primary
outcome measure for the cost-effectiveness analysis is the increase in health status on the primary outcome scales.
Within the cost-utility analysis, the primary outcome measure is quality-adjusted life years (QALYs) for which an
indirect preference-based technique will be used. In the self-management study we will also look at the estimation
of health effects on informal caregivers. Cost outcomes in the cost-of-illness study will be computed with a cost
questionnaire and linkage of several databases will be used to derive outcomes in the record linkage study,
Discussion: €-Restore4Stroke will provide new insights and evidence for the economic impact of psychosocial
consequences after stroke. Besides being innovative in various ways (i.e. focussing on the chronic phase after
stroke and including personal factors as possible determinants of long-term re-integration including quality of life
in a prospective longitudinal design), a major strength of €-Restore4Stroke is that we include impact on informal
caregivers. The outcomes of this study will provide health care decision makers with valuable and necessary
information regarding stroke care related decisions.
Trial registration: NTR3051 (RCT Self-management), NTR2999 (RCT Augmented Cognitive Behavioural Therapy)
Background
Stroke has a major socio-economic impact worldwide
and is the leading cause of disabilities in the Western
world. It is estimated that the worldwide prevalence of
stroke is 0.2% of the world population. Of the people
who suffer from a stroke, 30% die, 30% are left function-
ally disabled and 40% have a successful recovery with
minor to no disabilities [1]. It is estimated that by 2023
t h ea b s o l u t en u m b e ro fp a t i e n t se x p e r i e n c i n gaf i r s t
stroke will increase, in comparison with 1983, by 30%
worldwide [2]. The disease impact of stroke is consider-
able on stroke patients and on their informal caregivers.
More than 50% of the stroke survivors return to their
homes after being dischargedf r o mt h eh o s p i t a l[ 3 ] .A t
home, these survivors and their informal caregivers have
to deal with the long term consequences of stroke,
which are seen in physical, psychological and social
areas of functioning [4,5].
Not only the clinical, but also the financial burden of
stroke is considerable [6]. Currently, approximately 3-
4% of total health care expenditures in Western
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ernments are cutting down on expenditures for health
care, while on the other hand the health care sector is
facing an increased demand for stroke care, due to
demographic changes (e.g. an aging population) and
changing attitudes towards health care (e.g. more
demanding society; value for money) [8]. The growing
demand for stroke care and the limited resources avail-
able for health care, have led to an increased interest in
the economic aspects of stroke. The last few years have
shown a remarkable increase in the publication of eco-
nomic studies on stroke [7]. A Pubmed search combin-
ing “Cerebrovascular disorders” and “Costs and cost-
analysis” shows that since 1990 the number of stroke
studies including costs have increased in both absolute
and relative terms. Figure 1 shows this development
from 1990 until 2010, the last year for which complete
data were available.
In general, these economic studies of stroke focus pri-
marily on physical aspects and clinical care [9-14]. It is
known that recovery from stroke also depends on psy-
chological and social aspects. To our current knowledge
there is no comprehensive economic study that investi-
gates the economic impact of stroke including
psychological and social aspects. This article presents
the design and methods of a study which aims on inves-
tigating and determining the economics of psychosocial
care after stroke. The present study, €-Restore4Stroke
(pronounce as e-Restore), is part of a Dutch national
consortium called Restore4Stroke. Within Restore4S-
troke, four large studies are executed aiming to improve
t h eq u a l i t yo fl i f eo fs t r o k ep a t i e n t sa n dt h ec o n c u r r e n t
effects on their informal caregivers. Three of these stu-
dies focus more on outcomes while the fourth, €-Restor-
e4Stroke, is designed, among other things, to investigate
the economic aspects of the other three studies.
Restore4Stroke
In addition to €-Restore4Stroke, the following three stu-
dies are embedded in Restore4Stroke: two randomized
controlled trials (RCTs) and a cohort study. The first
RCT, Restore4Stroke Self-Management (referred to as
Self-Management study), aims at enhancing self-man-
agement in stroke patients and their informal caregivers.
The second RCT, Restore4Stroke Augmented Cognitive
Behavioural Therapy (referred to as the Augmented
CBT study), aims at decreasing depression and anxiety
complaints in stroke patients. With the third study, the
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Figure 1 Development publications on cost analysis and cerebrovascular disorder studies.
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Page 2 of 12Restore4Stroke Cohort study (referred to as the Cohort
study), the course of quality of life in stroke patients
and their informal caregivers is investigated, and factors
predicting quality of life, including pre-stroke health
situation factors, stroke-related factors, personal factors
and partner factors are determined. In this design article
we will focus on the economic aspects of all four stu-
dies, for further details on the other aspects of the two
RCTs and the cohort we refer to publication elsewhere.
For current status updates you can also visit http://
www.restore4stroke.nl.
All studies described in this article are approved by a
legally recognized medical ethics committee. The Self-
Management study was approved by the Medical Ethics
Committee Utrecht Medical Center. The Augmented
CBT study was approved by the Committee On
Research involving Human Subjects (CMO) Arnhem/
Nijmegen. The Cohort study was approved by the Com-
mittee Research involving Human Subjects (CMO) St.
Antoniusziekenhuis, Nieuwegein. All ethics approval
committees are located in The Netherlands.
€-Restore4Stroke
The €-Restore4Stroke project consists of four sub-stu-
dies. Attached to both RCTs, an economic evaluation
study will be performed. Economic evaluation studies
compare two or more health care interventions and
investigate the relationship between costs and effects.
Furthermore, a cost-of-illness study will be performed
for the Restore4Stroke cohort. Cost-of-Illness studies
aim at determining the total costs of a disease for
society. Finally, the fourth sub-study within €-Restore4S-
troke is a record linkage study. In this study, we will
focus on changes in health care consumption 5 years
before and 5 years after stroke through register and
database linkage. An overview of all four studies is pro-
vided in Figure 2.
Methods
Aim and research questions
The overall €-Restore4Stroke aim is to fully capture the
economic impact of psychosocial care after stroke.
Looking at the 4 subprojects embedded in this study,
the following research questions will be answered:
￿ From a societal perspective, what are the costs and
effects of the Self-Management intervention in com-
parison with an education intervention?
￿ From a societal perspective, what are the costs and
effects of the Augmented CBT intervention in com-
parison with a computerized cognitive training
intervention?
￿ How do patterns of care received after stroke (in
terms of health care costs, productivity costs, costs
Restore4Stroke
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Figure 2 Overview Restore4Stroke.
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low-up period of the Cohort study and what is their
impact on the patient (in terms of health-related
quality of life, life satisfaction and emotional func-
tioning) in economic terms as well?
￿ How do patterns of health care consumption after
stroke (in terms of health care costs, productivity
costs, costs of informal care) change during the 5
years after stroke, in comparison with the 5 years
before stroke and what is the economic impact of
these changes from a societal perspective (record
linkage study)?
€-Restore4Stroke outcome measures
All studies included in the €-Restore4Stroke project will
be performed from a societal perspective meaning that
all costs and outcomes of both the interventions and
comparators will be included. Within the Restore4Stroke
programme, Quality of life (QOL) is considered both
from a general Health-Related Quality Of Life (HRQOL)
and domain-specific QOL perspective. The general
HRQOL perspective is operationalised as disease-specific
HRQOL measured with the Stroke Specific Quality of
Life (SS-QoL [15]), and generic HRQOL measured with
the 5-dimensional EuroQol (EQ-5D [16]). The domain-
specific perspective consists of the domains: participa-
tion measured with the Utrecht Scale for Evaluation and
Revalidation Participation (Utrechtse Schaal voor Eva-
luatie en revalidatie - Participatie or USER-p [17]),
emotional functioning measured with the Hospital Anxi-
ety and Depression Scale (HADS [18]) and subjective
well-being measured with 3 satisfaction questions. An
overview of the primary and secondary outcome mea-
sures of all studies embedded in the Restore4Stroke pro-
gramme is presented in Table 1.
Designs
The study design is distinctive for each study and will be
explained in the following section.
Self-Management study and Augmented CBT study
Both trial-based economic evaluations will involve a
combination of a cost-effectiveness analysis (CEA) and a
cost-utility analysis (CUA). Costs will be calculated in
various ways. Effects will be presented as clinical out-
comes, which are the primary outcome parameters of
both the Self-Management study (i.e. the UPCC) and
the Augmented CBT study (i.e. the HADS). In a CUA,
costs are calculated in a similar way as in a CEA, but
effects are usually expressed in quality-adjusted life
years (QALYs) [19]. A QALY combines two distinct
variables: quality or utility (the value which stroke
patients attach to their current health status) and quan-
tity (life years gained) of health. Utilities in both studies
will be derived from the Five-Dimensional Euroqol (EQ-
5D). The EQ-5D is chosen because it is a widely used
quality of life instrument, also in the field of stroke. To
estimate the incremental cost-effectiveness, the incre-
mental cost-effectiveness ratio (ICER) will be calculated
for both the CEA and CUA. If there are two alternative
interventions, their difference in cost (incremental cost)
is compared with their difference in outcomes (incre-
mental effect) by dividing the former by the latter. This
ratio is known as the ICER and is expressed as the
incremental cost per point improvement on the primary
outcome measure or otherwise costs per QALY.
In addition, in the Self-Management study we will
include a questionnaire to investigate the quality of life
of informal caregivers. Performing an economic evalua-
tion from a societal perspective means including all rele-
vant costs and effects, but economic evaluations of
health care interventions usua l l yt r e a tp a t i e n t sa si s o -
lated individuals in determining the relevant health
effects. Consequently, the quality of life of informal care
is usually neglected in these studies. To address this
issue, the CarerQOL [20] questionnaire will be included
in the Self-Management study.
Sample size calculation
The sample size calculation of the Self-Management
study is based on a method presented by Jones et al.
[21]. Based on two earlier intervention studies with the
UPCC [22,23], a standardised difference was calculated
representing the difference between the means/popula-
tion standard deviation. The studies resulted in two dif-
ferent outcomes: a difference in means of .2 and .3
respectively between the groups on the UPCC and a
mean SD of .35 and 0.6 respectively. Based on these stu-
dies, a standardised difference of .6 on the UPCC was
used for the power calculation (.2/.35 = .57). Based on
the method of Jones et al, 45 patients per group are
n e e d e db a s e do na na l p h ao f. 5a n dap o w e ro f8 0 % .
Assuming a drop-out rate of 15%, 106 patients (2 × 53)
will be recruited for this study.
Based on previous research, it has not been possible to
conduct a power calculation on the HADS as the psy-
chological intervention studies in the Cochrane review
[24] all used different outcome measures and not the
HADS. Hence, the sample size calculation for the Aug-
mented CBT study will be based on other measures and
is therefore identical to the sample size calculation for
the Self-Management study (2 × 53 = 106).
Setting and participants
Participants will be recruitedf r o mp a r t i c i p a t i n gh o s p i -
tals and rehabilitation centres in the Netherlands on the
basis of case finding. For the Self-Management study, a
minimum of 106 home-living mild stroke patients with
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t h eb a s i so ft h eU S E R - pw i l lb er e c r u i t e d ,t h r o u g ht h e i r
own physicians or nurse practitioners. For the Augmen-
ted CBT study, a minimum of 106 patients who have
depression and anxiety symptoms based on a cut-off
score > 7 on the depression subscale of the HADS will
be included. Patients will be recruited through a rehabi-
litation specialist, nurse practitioner or psychologist. For
both studies, written informed consent for participation
is obtained from both participants and their partners (if
included) after recruitment.
Timeline
For the Self-Management study, eligible patients and
their informal caregivers will be randomized towards the
Self-Management Intervention (SMI) or education inter-
vention after baseline measurement T0. Both SMI and
education intervention have a duration of 10 weeks and
post-treatment measurement (T1) will take place at 3
months after T0. Two follow-up measurements (T2 and
T3) will take place at 6 and 12 months after T0. For the
Augmented CBT study, eligible patients will be rando-
mized towards the Augmented CBT intervention the
computerized cognitive training intervention after base-
line measurement T0. Post-treatment measurements
(T1) will take place 4 months from T0, and two follow-
up measurements (T2 and T3) will take place 10 and 16
months from T0. Cost measurements for both studies
are presented in Figure 3. At all measurement points,
cost data will be asked retrospective varying from 2 to 6
months retrospective.
Interventions
The SMI is designed as an effective proactive coping
group intervention for both stroke patients and their
informal caregivers, with a duration of ten weeks [25].
The intervention, including seven group sessions, will be
provided by two specially trained therapists experienced
in group counselling and working with brain injury
patients. The sessions will be organised in the participat-
i n gi n s t i t u t i o n s .G r o u ps e s s i o n sa r ea i m e da ts e t t i n g
goals and attaining them. These goals relate to different
Table 1 Outcome measures Restore4Stroke (x: cost questionnaires, p: primary outcome measure, s: secondary
outcome measure)
Self-Management study Augmented CBT study Cohort study
T0 T1 T2 T3 T0 T1 T2 T3 T1 T2 T3 T4 T5
Primary outcomes €-Restore4Stroke
Cost Questionnaire x x x x xxxx x
a x
a x
a x
a
CarerQol Questionnaire s s s s
Primary outcomes Restore4Stroke
EQ-5D
b ssssssss ssss
HADS
c s s s ppppsssss
USER-P
d ss sssssppppp
SS-Qol-12
e ss sssss ssss
Life satisfaction s s s ssss ssss
Other outcomes
UPCC
f pppp
VAS
g ss s
ECSI
h ss s
PSDRS
i ssss
GSES
j pppp
GAS
k ssss
aThe cost questionnaire used in the cohort study is a short questionnaire (11 items) compared to the cost questionnaire used in the Self-Management and
augmented CBT Study (19 items)
b5 Dimensional EuroQol
cHospital Anxiety and Depression Scale
dUtrecht Scale for Evaluation and Regabilitation Participation (Utrechtse Schaal voor Evaluatie en Revalidatie - Participatie)
eStroke Specific Quality of Life
fUtrecht Proactive Coping Competence list
gVisual Analogue Scale
hExpanded Caregiver Strain Index
iPost Stroke Depression Rating Scale
jGeneral Self-Efficacy Scale
kGoal Attainment Scale
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society, and negative emotions. Six group sessions (two
hours each) will be held in participating hospitals during
the first six weeks and one booster session (for exchan-
ging experiences and repeating theoretical concepts) will
be held at 10 weeks from baseline. The control group
will receive an education intervention aimed at provid-
ing passive information. One trained health care profes-
sional will provide three group sessions (one hour each)
in the first 6 weeks concerning different themes (i.e. the
brain, a stroke, and prevention of a recurrent stroke)
and a booster session at week nine from baseline; all are
held in the participating institutions.
The Augmented CBT treatment will focus on register-
ing, recognising and altering mood, negative thoughts,
cognitions and emotional symptoms that comprise
depressive problems as well as anxiety. The intervention
will be provided by an experienced health care psycholo-
gist in the participating institutions (10-12 sessions),
where occupational therapists and/or movement thera-
pists will be enrolled in the intervention as co-therapists
(three to four sessions). The intervention is an indivi-
dual therapy, in which patients are expected to
participate in a total of 13 to 16 individualised sessions,
in a time-span of four months. Test assistants or assis-
tant psychologists working in the participating institu-
tion will assist execution of the control intervention
programme, the computerized cognitive training pro-
gramme CogniPlus, aimed at improving general cogni-
tive functioning. Patients will participate in a total of 13
to 16 sessions in a time-span of for months, equal to
the Augmented CBT intervention. The programme is
self-supporting as most tasks can be executed without
assistance.
Outcome measures
In Figure 2 the outcome measures of the Restore4Stroke
program in general and the four studies embedded in
this program are shown. The primary outcome measure
for the CEA will be the increase in health status as mea-
sured by the UPCC (Self-Management study) and the
HADS (Augmented CBT study). Within the CUA, the
primary outcome measures are QALYs for which an
indirect preference-based technique will be used. In this
technique, the patient’s health status will be measured
by means of the EQ-5D and weights that incorporate
T0 (baseline)   T1 (4 months 
post baseline) 
T2 (10 months 
post baseline) 
T3 (16 months 
post baseline)  
Cost data 3 months 
retrospective 
Cost data 4 months 
retrospective 
Cost data 6 months 
retrospective 
Cost data 6 months 
retrospective 
T0 (baseline)  T1 (3 months 
post baseline) 
T2 (6 months 
post baseline) 
T3 (12 months 
post baseline)  
Cost data 3 months 
retrospective 
Cost data 3 months 
retrospective 
Cost data 3 months 
retrospective 
Cost data 6 months 
retrospective 
Figure 3 Cost measurements Self-Management study (top) and Augmented CBT study (down).
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used to calculate utilities. The EQ-5D is chosen because
it is a widely used quality of life instrument (nationally
and internationally). The EQ-5D contains five dimen-
sions of health-related quality of life; namely mobility,
self-care, daily activities, pain-discomfort and depres-
sion/anxiety [17]. Each dimension can be rated at three
l e v e l s :n op r o b l e m s ,s o m ep r o b l e m sa n dm a j o rp r o -
blems. The five dimensions can be summed into a
health state. Utility values can be calculated for these
health states, using preferences elicited from a general
population, the so-called Dolan algorithm [26]. The uti-
lity values derived from the Dolan algorithm will be
used to compute QALYs. The Dolan algorithm has been
established using a general population from the UK. In
2006, a Dutch algorithm became available [27] using
Dutch tariffs instead of UK tariffs to compute QALYs.
The utilities at the three time points will be used to
compute a QALY score by means of the area under the
curve method. Furthermore, the EQ-5D consists of a
visual analogue scale (VAS) ranging from zero (worst
imaginable health state) to 100 (best imaginable health
state). The reliability and validity of the EQ-5D has been
studied and established [28,29]. The base case analysis
will use the individual utility score of the patient based
on the EQ-5D.
To estimate the health effects on informal caregivers,
the CarerQOL questionnaire has been chosen. This
instrument was tested positively in terms of validity and
feasibility in extensive research by Hoefman et al. [20].
The CarerQol questionnaire consists of two compo-
nents, namely the CarerQol-7D and the CarerQol-VAS.
The CarerQol-7D refers to seven dimensions, each
represented by one question on the questionnaire. The
seven dimensions are: fulfilment, relational dimension,
mental health dimension, social dimension, financial
dimension, perceived support and physical dimension
The purpose of the CarerQol 7D is to help caregivers
indicate their situation with respect to a particular
dimension on one of three levels (I have no/some/a lot
of...). The CarerQol-VAS is a visual analogue scale,
where caregivers can indicate how happy they feel, ran-
ging from 0 (completely unhappy) to 10 (completely
happy). The CarerQol questionnaire will be computed
at every measurement point of the Self-Management
study, T0-T3.
Cost analysis
The following cost categories will be distinguished and
included in this study: intervention costs, costs for the
health care sector, patient and family costs and costs
outside the health care sector. Intervention costs will
include all the costs that contribute to the development
and administration of the SMI and Augmented CBT.
Health care sector costs are related, for instance, to gen-
eral practitioner (GP) visits, hospital visits and medica-
tion. Patient and family costs concern, for instance,
travel costs, costs of informal care, productivity losses
and home adjustments. Costs outside the health care
sector will be measured as productivity costs.
To measure the actual use of resources, data will be
obtained using combined sources (registrations by pro-
fessionals and a cost questionnaire for the patients
conducted at al measurement points, T0 - T3, of both
t h eS e l f - M a n a g e m e n ts t u d ya n dt h eA u g m e n t e dC B T
study). Resources used relating to the interventions
will be based on the registered time all professionals
spent on the treatment. All use of resources by the
patient and their family, within and outside the health
care sector will be measured by means of a cost ques-
tionnaire which will continuously record volumes of
utilization during the follow-up period. The cost ques-
tionnaire has been designed especially for the partici-
pants in both RCTs, based on existing questionnaires
[30]. The questionnaire consists of 20 items and will
cover three areas of expenses, namely expenses of
(inability to perform) daily activities, expenses of health
care consumption and expenses of help received
(material and immaterial).
Valuation
The valuation of health care costs, patient and family
costs will be based on the updated Dutch manual for
cost analysis in health care research [31]. This manual
recommends using standardised cost prices. In brief, the
manual recommends that prices of informal care should
be based on shadow prices for unpaid work (meaning a
standard cost price based on general hourly wages).
Costs of transport will be calculated as the mean dis-
tance per destination multiplied by costs per kilometre.
Costs of medication will be calculated using prices
based on the Daily Defined Dosage (DDD) taken from
the Dutch Pharmacotherapeutic Compass [32], indicat-
ing the mean medication usage per adult a day, includ-
ing the government-imposed discount for patients paid
by the pharmacy. Productivity costs will be calculated by
means of the friction cost method based on a mean
added value of the Dutch working population. The fric-
tion costs method takes into account production losses
confined to the period needed when it is necessary to
replace a sick employee (currently 160 days [31]). In
case of uncertainty we will use a conservative estimate
(i.e. the lowest cost price). Cost prices will be expressed
in Euros on the basis of cost prices of 2011. If necessary,
existing cost prices will be updated to 2011 using the
consumer price index (CPI) [32]. In this case, discount-
ing is irrelevant as the follow-up period is less than a
year.
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The power analyses in both trial-based economic evalua-
t i o n sw i l lb eb a s e do nt h eR C T s .T h ep r i m a r y( b a s e -
case) analyses will be performed according to the inten-
tion-to-treat principle. This means that data from all
participants will be used, regardless of whether they
received the intervention or not. For the analyses we
will use SPSS statistical software and Excel.
Respondents for whom at least 75% of the data per
measurement instrument are available will be included
in the analysis. Missing data on item level will be
handled using SPSS missing value analysis. Completely
missing measurements will be handled using multiple
imputation (MI). A baseline analysis will be performed
to examine the comparability of groups at baseline for
both costs and outcomes. If necessary, methods will be
applied to control for differences in baseline [33].
Despite the usual skewed distribution of costs, the arith-
metic means is generally considered the most appropri-
ate measure for describing cost data [33]. Therefore
arithmetic means (and standard deviations) will be pre-
sented. In case of skewed cost data, non-parametric
bootstrapping will be used to test for statistical differ-
ences in costs between the intervention and control
group. Non-parametric bootstrapping is a method based
on random sampling with replacement based on the
participants’ individual data [34]. The bootstrap replica-
tions will be used to calculate 95% confidence intervals
around the costs (95% CI), based on the 2.5 and 97.5
percentiles. If cost data are distributed normally, t-tests
will be used.
ICERs will be calculated for both the CEA and CUA.
The ICER will be calculated as follows: ICER = (Ci -
Cc)/(Ei - Ec), where Ci is the annual total cost of the
new intervention, Cc is the annual total cost of the com-
parator, Ei is the effects at the 6 month follow-up for
the new intervention and Ec is the effect at 6 month fol-
low-up for the comparator.
The robustness of the ICER will be checked by non-
parametric bootstrapping. Bootstrap simulations will
also be conducted in order to quantify the uncertainty
around the ICER, yielding information about the joint
distribution of cost and effect differences. The boot-
strapped cost-effectiveness ratios will be plotted subse-
quently in a cost-effectiveness plane, in which the
vertical line reflects the difference in costs and the hori-
zontal line reflects the difference in effectiveness. The
choice of treatment depends on the maximum amount
of money that society is prepared to pay for a gain in
effectiveness, which is called the ceiling ratio. Therefore,
the bootstrapped ICERs will also be depicted in a cost-
effectiveness acceptability curve, showing the probability
that the intervention is cost-effective using a range of
ceiling ratios.
In addition, to demonstrate the robustness of our
base-case findings, a multi-way sensitivity analysis will
be performed. In the sensitivity analysis uncertain fac-
tors of assumptions in the base-case analysis will be cal-
culated in order to assess whether the assumptions have
influenced the ICER, for example by varying cost-prices
and volumes between minimum and maximum [34].
Cost-of-illness (COI) study as part of the Cohort study
A COI study will be performed to gain insight into care
received after stroke and the economic consequences of
psychosocial care in particular. A COI study aims at
identifying and measuring all the costs of a particular
disease, including the direct, indirect and intangible
dimensions [35]. This COI study will be embedded in
the Cohort study, focussing on the course of quality of
life in stroke patients and their informal caregivers, and
determining factors predicting quality of life, including
pre-stroke health situation factors, stroke-related factors,
personal factors and partner factors after stroke. As it is
embedded in the Cohort study, the COI study will be
related to outcomes of the cohort in a cost-outcome
description.
Sample size calculation
With an inclusion of 500 patients and an expected drop-
out rate of 40%, 300 patients should be available for
long term analysis (to identify early predictors of long
term consequences). For instance, to analyse the course
of reintegration and quality of life (linear regression ana-
lysis), a total of 300 patients allows regression models
with 15 predictors and 15 to 20 subjects per predictor.
Setting and participants
For the COI study 500 patients will be recruited from
the stroke units in 6 participating hospitals in the Neth-
erlands. If present, informal caregivers will also be
recruited for the Cohort study to estimate levels of bur-
den, though their presence is not a necessity for the
COI study. Written informed consent for participation
is obtained after recruitment.
Timeline
Cost measurements are conducted at 2 months (T2), 6
months (T3), 1 year (T4) and 2 years (T5) post stroke,
which is parallel to the measurement points of other
questionnaires included in the Cohort study. Retrospec-
tive data covering a fixed period prior to measurement
points will be extracted from the questionnaires: 2
months at T2, 4 months at T3, 6 months at T4 and 6
months at T5. To avoid recall bias after the two year
follow-up, a fixed period of maximum 6 months prior
to T5 is chosen. An overview of the timeline for the
cost-of-illness cost measurements is presented in Figure
4.
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For the purpose of the COI study, necessary cost infor-
mation will be retrieved through a specially designed
short cost questionnaire of 11 items covering the costs
of psychosocial care after stroke. A simple questionnaire
is preferred, for the purpose of the COI study; accord-
ingly the questionnaire has been adapted from previous
trial-based economic evaluations studies.
The questionnaire consists of 3 subscales: health care
costs, productivity costs and costs of informal care. The
dimension of health care costs is captured with 8 items,
productivity costs with 2 items and costs of informal
care with 1 item. Care received will be measured in
absolute numbers, representing visiting times and hours,
day and nights spent on health care services and infor-
mal care. Due to the fact that the questionnaire is
adjusted to be disease-specific every time it is being
used, no research has been done on the validity of this
questionnaire for stroke research. Nevertheless, the
validity of self-reported measurements has been proven
earlier in a large multi-centre clinical trial [36].
Cost analysis
Essentially, there a two approaches to establish the costs
of illness: the top-down approach and the bottom-up
approach [37]. Scientific publications so far show that
the majority of COI studies have been performed using
a top-down method, based on calculating the costs of a
disease through national databases [8]. The COI study
described in this article is designed to use a bottom-up
method in which a group of patients who have suffered
from a stroke (the cohort population) will be asked
what the costs of their disease are, through a specially
designed cost questionnaire, instead of using databases.
The estimation of costs will be divided into two steps.
The first step is estimating the quantity of health inputs
used and the second step is to estimate the unit costs of
t h ei n p u t su s e d[ 3 8 ] .T h ec o s t sa r et h e ne s t i m a t e db y
multiplying unit costs by the quantities. One of the
main advantages of the bottom-up approach is that
detailed data can be obtained regarding costs outside
the health care sector such as the productivity losses,
which will be investigated in this study [37]. Other
advantages are that the bottom-up approach is much
more accurate in measuring costs than the top-down
approach, which is more likely to present misallocation
of costs [38]. For example, national health care expendi-
tures may either under or overestimate the total direct
costs, where the bottom-up approach gives a more accu-
rate estimate. Furthermore, a serious problem with the
top-down approach is that all costs are attributed to the
primary diagnosis [37]. This is a serious problem con-
sidering that a relevant part of all hospital discharges
involve patients with multiple diagnoses. This is not an
issue, and therefore an advantage, with the bottom-up
approach. In addition, a follow-up period of 2 years will
be used in this study, which will make it possible to dis-
tinguish patterns in health care consumption over time.
Valuation
Within the COI study, the valuation of health care con-
sumption, productivity losses and the costs of informal
health care will be similar to the trial-based economic
evaluation. This means that the valuation in general will
be based upon the Dutch manual for cost analysis in
health care research [39].
Statistical analysis
Missing data and skewed data will be handled similar as
in the economic evaluation study, hence respondents for
whom at least 75% of the data per measurement instru-
ment are available will be included in the analysis and
missing data on item level will be handled using SPSS
missing value analysis. Completely missing measure-
ments will be handled using multiple imputation (MI).
Arithmetic means will be used to describe cost data,
T2 (2 months 
post stroke) 
T3 (6 months 
post stroke) 
T4 (12 months 
post stroke) 
T5 (24 months 
post stroke)  
Cost data 2 months 
retrospective 
Cost data 4 months 
retrospective 
Cost data 6 months 
retrospective 
Cost data 6 months 
retrospective 
Figure 4 Cost measurement Cohort study.
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metric bootstrapping will be used to test for statistical
differences in costs between the intervention and con-
trol group. The bootstrap replications will be used to
calculate 95% confidence intervals around the costs
(95% CI), based on the 2.5 and 97.5 percentiles. If cost
data are distributed normally, t-tests will be used.
Concerning the cost measurements, a month of miss-
ing data exists between T2 and T3 and 6 months of
missing data exists between T4 and T5. To deal with
the issue we will use interpolation to construct new data
points for these periods. This will be done by calculating
mean cost data for the period of 6 months (T3) to 12
months (T4) post stroke and the period of 18 months to
24 (T5) months post stroke. These data will be used to
estimate the period between 12 months to 18 months
post stroke.
We will do a comparative analysis to estimate differ-
ences in costs between 1 year post stroke and 2 years
post stroke. Additionally, we will compare cost out-
comes and effect outcomes on the primary outcome
scales. Furthermore, we will try to determine high-cost
users and low-cost users of health care after stroke. In
the latter analysis, high-cost users and low-cost users will
be identified by specific patients’ characteristics, costs
being the dependent variable and patient characteristics
being independent variables.
Record linkage study (RLS)
A RLS will be conducted in which the stroke cases
registered in the Maastricht University Medical Centre
(MUMC) Stroke Register, MUMC Medical Administra-
tion, the Mental Health Case Register (MHCR) and GP
registrations in the same catchment area, will be linked.
Since the available data linking these registers is limited,
linking these databases will provide updated and
extended information about the current estimates of
care consumption and the hypothesis that problems
occurring after stroke, such as depression, anxiety and
dementia are underestimated and under-diagnosed. The
aim of this study is to examine how patterns of health
care consumption after stroke (in terms of health care
costs, productivity costs, costs of informal care) change
during the 5 years after stroke, in comparison with the
5 years before stroke and what the economic impact is
of these changes from a societal perspective.
Sample size calculation
Sample size calculation was not performed because all
available patients will be used for data analysis.
Setting and participants
As mentioned before, four stroke registers will be linked.
The MUMC has been chosen because it is evident that
t h em a j o r i t yo fs t r o k es u r v i v o r si nt h ea r e aw i l lb e
admitted to the hospital. Since the MUMC is the only
(academic) hospital in that area, it is most likely that
stroke patients will be registered in the MUMC data-
base. The MUMC uses a general Medical Administra-
tion Database and a specific Stroke Database to collect
data on stroke patients. In theory, these databases
should overlap 100%, but further research should prove
whether this is true. Therefore, we will use both data-
bases capture all stroke cases registered. The organisa-
tions involved informed patients about data collection,
which means that separate informed consent is not
necessary for our record linkage. Approval for the use of
these databases for this specific purpose will be
requested from the Medical Ethics Committee of the
University Hospital Maastricht and Maastricht
University.
The MHCR has collected data cumulatively on the
psychiatric hospital, the community mental health cen-
tre, the psychiatric department of the MUMC, the com-
munity psychiatric outreach team, psycho-geriatric
nursing homes, sheltered housing, child psychiatric ser-
vices, services for the mentally impaired, alcohol and
drug abuse services etc. The MHCR has also collected
demographic and diagnostic data in a region with a
population of around 200,000. The region where this
research will take place is a city of Maastricht (120,000
inhabitants), a relatively small city in the far south of
the Netherlands, and its surrounding area (80,000
inhabitants).
The MUMC is the only hospital in the city of Maas-
tricht and the surrounding area with both a regional
and a top-referral care function. In the MUMC, all
patients are registered with an ICD-9 or ICD-10 classifi-
cation, depending on the year of admission.
Timeline
In this RLS, changes in health care consumption during
the five years after stroke in comparison with the five
years before stroke and what the economic impact of
these changes is, will be studied form a societal perspec-
tive. Stroke patients discharged from the MUMC
between 2000 and 2005 will be included in this study,
which will allow us to analyse patient data from 1995
until 2010 (analyses from5 years before first stroke case
until 5 years after last stroke case).
Cost analysis and valuation
Through anonymous record linkage health care con-
sumption within the 10-year reference period (from 5
years before and after stroke) will be analysed. The first
step in the analysis is to examine this consumption
before, during and after stroke. In an additional analysis
the health care costs will be calculated based on quanti-
ties derived from the MHCR and GP registrations. The
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research [39] will be used for the valuation of these
health care costs.
Statistical analysis
The statistical processing program SPSS will be used to
link all databases. Databases will be linked anonymously,
meaning that specific codes based on different variables
will be computed and used to compare patients, instead
of specific patient information. To estimate health care
consumption before and after stroke, we will divide all
stroke patients in 2 equal groups. Therefore, high-cost
users of health care after stroke will be compared to
low-cost users of health care after stroke. Similar as in
the COI-study, we will estimate the differences between
high-cost users and low-cost users using regression
analysis.
Discussion
The Restore4Stroke programme aims not only to pro-
vide effective interventions, but will also help to identify
stroke patients and their informal caregivers at risk of
developing long-term problems and refer them to the
proper health care professional. The major strength of
this programme is that it allows us to combine several
powerful research methods into a comprehensive study
and to oversee our research outcomes from an aggregate
level.
The Restore4Stroke programme is innovative for sev-
eral reasons. First, the family-centred perspective results
in investigating the quality of life in both patients and
their informal caregivers. Second, the focus of Restor-
e4Stroke on personal factors as possible determinants of
long-term re-integration and on quality of life in a pro-
spective longitudinal design is innovative in comparison
with studies focussing on physical and functional conse-
quences [40]. Third, the comprehensive and multidisci-
plinary character of Restore4Stroke should provide new
and necessary information which can serve several dif-
ferent medical sciences and decision makers.
Within Restore4Stroke, the present study, €-Restor-
e4Stroke, will provide new economic insights and evi-
dence for the rehabilitation of psychosocial
consequences occurring in the chronic phase after
stroke. One of the strengths of the €-Restore4Stroke
s t u d yi st h a tw ei n c l u d et h ee s t i m a t i o no fh e a l t he f f e c t s
on informal caregivers. By adding the CarerQOL ques-
tionnaire to our research we not only perform an actual
full economic evaluation from a societal perspective, but
we are also able to expose the true scope of effects
shown by the Self-Management study. Another strength
of this study is the inclusion of the RLS, which will give
new insights in health care consumption five years
before and five years after stroke. To our current knowl-
edge, no RLS has been done recently, although more
information has become available about the conse-
quences of stroke. In addition, we will be able to com-
pare our results to a RLS conducted in 2001 [41] and
determine what has changed since. Furthermore, we
expect that the information we gain from the economic
evaluation of the two suggested interventions will add
impact on the implementation of these interventions in
health care.
Current study status
The Restore4Stroke research programme started in Sep-
tember 2010. The €-Restore4Stroke study has almost
finished its preparation phase and will start its data col-
lection parallel to the RCTs and cohort data collection
to which it is attached. The Cohort study, the Augmen-
ted CTB study and the Self-Management study received
approval from the Medical Ethics Committee.
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